Showing results (21-30 of 57) with videos related to
Sort By:
Pageof 6
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2014
The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humansMartin E Dowty, Jinyan Lin, Tim F Ryder, et al.Chemosphere|October 2, 2007
Approach for extrapolating in vitro metabolism data to refine bioconcentration factor estimatesChristina E Cowan-Ellsberry, Scott D Dyer, Susan Erhardt, et al.Clinical Pharmacology and Therapeutics|November 19, 2016
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release TofacitinibM Lamba, M M Hutmacher, D E Furst, et al.Clinical Pharmacology in Drug Development|May 4, 2022
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a 14 C-Microtracer ApproachRavi Shankar P Singh, Martin E Dowty, Mikhail Salganik, et al.Clinical and Experimental Rheumatology|March 12, 2016
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritisJennifer A Hodge, Thomas T Kawabata, Sriram Krishnaswami, et al.Clinical Pharmacology and Therapeutics|May 27, 2024
Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified-Release Dosage FormVivek Purohit, Kazuko Sagawa, Hao-Jui Hsu, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 28, 2016
Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance MechanismsLouis Leung, Xin Yang, Timothy J Strelevitz, et al.European Journal of Drug Metabolism and Pharmacokinetics|March 30, 2024
Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy IndividualsXiaoxing Wang, Martin E Dowty, Sakambari Tripathy, et al.Journal of Clinical Pharmacology|December 22, 2017
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque PsoriasisChristopher Banfield, Matthew Scaramozza, Weidong Zhang, et al.The Journal of Pharmacology and Experimental Therapeutics|October 13, 2007
Small-molecule melanin-concentrating hormone-1 receptor antagonists require brain penetration for inhibition of food intake and reduction in body weightX Eric Hu, John A Wos, Martin E Dowty, et al.Pageof 6